NCT01701219 - Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions

Staphylococcus Aureus BacteremiaMethicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia

Interventions

DRUG

Ceftaroline fosamil

Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)

Trial Locations (27)

11418

Investigational Site, Jamaica

22003

Investigational Site, Annandale

24014

Investigational Site, Roanoke

29605

Investigational Site, Greenville

30030

Investigational Site, Decatur

31201

Investigational Site, Macon

32504

Investigational Site, Pensacola

34994

Investigational Site, Stuart

35294

Investigational Site, Birmingham

40202

Investigational Site, Louisville

43620

Investigational Site, Toledo

46845

Investigational Site, Fort Wayne

48073

Investigational Site, Royal Oak

48201

Investigational Site, Detroit

48202

Investigational Site, Detroit

48236

Investigational Site, Grosse Pointe Woods

60612

Investigational Site, Chicago

77030

Investigational Site, Houston

90502

Investigational Site, Torrance

91342

Investigational Site, Sylmar

94110

Investigational Site, San Francisco

95817

Investigational Site, Sacramento

06102

Investigational Site, Hartford

02111

Investigational Site, Boston

03246

Investigational Site, Laconia

07753

Investigational Site, Neptune City

07102

Investigational Site, Newark